Hosted on MSN24y
What Immunohistochemistry (IHC) Can Tell You
Medically reviewed by Doru Paul, MD Immunohistochemistry (IHC) is a special test used by pathologists to detect specific ...
pharmaphorum14d
Enhertu gets first okay for HER2-ultralow breast cancer
AstraZeneca and Daiichi Sankyo have claimed their seventh FDA approval for Enhertu, getting the go-ahead for the blockbuster ...
The American Journal of Managed Care11d
FDA Approves First HER2-Ultralow Companion Diagnostic, Expanding Treatment Eligibility
Roche’s PATHWAY HER2 (4B5) test helps identify patients with HER2-ultralow breast cancer, who may be eligible for targeted ...
Targeted Oncology6d
FDA Expands PATHWAY HER2 (4B5) Test to Include HER2-Ultralow Status
The PATHWAY HER2 (4B5) test is now FDA-approved to assess HER2-ultralow status in metastatic breast cancer, expanding its ...
Nature4y
Five easy and effective methods to validate antibodies
In the 25 years since the company’s launch, she estimates that LSBio has performed IHC testing on more than 80,000 antibodies and she has personally evaluated more than 25,000 different ...
pharmaphorum10mon
Roche gets EU okay for first HER2-low test kit
The availability of a simple immunohistochemical (IHC) test for HER2-low status is seen as critical to the successful rollout of Enhertu (trastuzumab deruxtecan) in this category of breast cancer ...
The American Journal of Managed Care14d
FDA Approves Trastuzumab Deruxtecan for HER2-Low/Ultralow Breast Cancer
The approval is based on findings from a phase 3 study which demonstrated the drug’s superiority over chemotherapy.
FDA approval expands earlier use of Enhertu for metastatic breast cancer
The U.S. Food and Drug Administration has approved Enhertu (trastuzumab deruxtecan) for the treatment of adult patients with ...